"MAP Kinase Kinase 1" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
An abundant 43-kDa mitogen-activated protein kinase kinase subtype with specificity for MITOGEN-ACTIVATED PROTEIN KINASE 1 and MITOGEN-ACTIVATED PROTEIN KINASE 3.
Descriptor ID |
D048369
|
MeSH Number(s) |
D08.811.913.696.620.682.700.565.100 D08.811.913.696.620.682.725.200.100 D12.644.360.440.100 D12.776.476.440.100
|
Concept/Terms |
MAP Kinase Kinase 1- MAP Kinase Kinase 1
- MKK1 Protein Kinase
- MAP2K1 Protein
- Mitogen-Activated Protein Kinase Kinase 1
- Mitogen Activated Protein Kinase Kinase 1
- MKK-1 Protein Kinase
- MKK 1 Protein Kinase
- MEK-1 Protein Kinase
- MEK 1 Protein Kinase
- MAPK Kinase 1
- MEK1 Protein Kinase
|
Below are MeSH descriptors whose meaning is more general than "MAP Kinase Kinase 1".
Below are MeSH descriptors whose meaning is more specific than "MAP Kinase Kinase 1".
This graph shows the total number of publications written about "MAP Kinase Kinase 1" by people in this website by year, and whether "MAP Kinase Kinase 1" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
Year | Major Topic | Minor Topic | Total |
---|
1997 | 0 | 3 | 3 |
1998 | 0 | 1 | 1 |
1999 | 0 | 2 | 2 |
2000 | 0 | 1 | 1 |
2001 | 0 | 3 | 3 |
2003 | 0 | 1 | 1 |
2004 | 1 | 1 | 2 |
2005 | 0 | 1 | 1 |
2009 | 0 | 2 | 2 |
2010 | 0 | 1 | 1 |
2011 | 0 | 1 | 1 |
2012 | 2 | 1 | 3 |
2013 | 0 | 2 | 2 |
2015 | 1 | 0 | 1 |
2017 | 0 | 1 | 1 |
2018 | 1 | 0 | 1 |
2019 | 2 | 1 | 3 |
To return to the timeline,
click here.
Below are the most recent publications written about "MAP Kinase Kinase 1" by people in Profiles.
-
Considering adjuvant therapy for stage II melanoma. Cancer. 2020 03 15; 126(6):1166-1174.
-
Erdheim-Chester disease with concomitant Rosai-Dorfman like lesions: a distinct entity mainly driven by MAP2K1. Haematologica. 2020 01; 105(1):e5-e8.
-
Comprehensive Clinical Trial Data Summation for BRAF-MEK Inhibition and Checkpoint Immunotherapy in Metastatic Melanoma. Oncologist. 2019 11; 24(11):e1197-e1211.
-
Oral MEK 1/2 Inhibitor Trametinib in Combination With AKT Inhibitor GSK2141795 in Patients With Acute Myeloid Leukemia With RAS Mutations: A Phase II Study. Clin Lymphoma Myeloma Leuk. 2019 07; 19(7):431-440.e13.
-
Efficacy of MEK inhibition in patients with histiocytic neoplasms. Nature. 2019 03; 567(7749):521-524.
-
Frequency of MAP2K1, TP53, and U2AF1 Mutations in BRAF-mutated Langerhans Cell Histiocytosis: Further Characterizing the Genomic Landscape of LCH. Am J Surg Pathol. 2018 07; 42(7):885-890.
-
SMAD4 Loss Is Associated with Cetuximab Resistance and Induction of MAPK/JNK Activation in Head and Neck Cancer Cells. Clin Cancer Res. 2017 Sep 01; 23(17):5162-5175.
-
ROS1 Fusions Rarely Overlap with Other Oncogenic Drivers in Non-Small Cell Lung Cancer. J Thorac Oncol. 2017 05; 12(5):872-877.
-
Metabolic Rewiring by Oncogenic BRAF V600E Links Ketogenesis Pathway to BRAF-MEK1 Signaling. Mol Cell. 2015 Aug 06; 59(3):345-358.
-
The biology and clinical development of MEK inhibitors for cancer. Drugs. 2014 Dec; 74(18):2111-28.